Global Caspofungin market, which accrued nearly 478.96 (USD Million) in 2019, is set to record the CAGR of nearly 0.21% over the period from 2020 to 2026
The global Caspofungin market, which accrued nearly 478.96 (USD Million) in 2019, is set to record the CAGR of nearly 0.21% over the period from 2020 to 2026. The report offers assessment and analysis of the Caspofungin market on a global and regional level. The study provides an in-depth assessment of the industry competition, limitations, sales revenues, opportunities, emerging trends, and industry-validated information. The report offers historical data from 2017 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Million).
Caspofungin also referred to as Caspofungin acetate is the first kind of anti-fungal medicine of echinocandins class that was launched in 2001. It has received approval from the U.S. FDA for treating adults as well as pediatric patients above age of 3 months. Furthermore, the drug is a new kind of antifungal lipopeptides compound that restricts enzyme beta-1, 3-D-glucan synthase synthesis. Apparently, the enzyme helps in forming of beta 1, 3-glucan polymer that is a key part of cell wall of pathogenic fungi. Caspofungin is used for treating invasive fungal infections, which are key cause of mortality in hospitalized patients, in the subjects as the drug has proved to be safe and having huge therapeutic potential.
Furthermore, Caspofungin has proved as an effective fungicidal agent against candida species like triazole resisting isolates and has demonstrated triphasic non-linear pharmacokinetics. Reportedly, clinical trials have displayed fungi static activities against aspergillus species. Moreover, the drug possesses short alpha-phase half-life of nearly one to two hours as well as beta-phase half-life of approximately nine to eleven hours that displays log linearity. In addition to this, Caspofungin is inoculated in patients through intravenous route of administration.
Market Growth Dynamics
The drug has proved to be the best therapeutic alternative for treating subjects suffering due to candida infections, aspergillus infections, and candida esophagitis. According to NCBI, the drug has exemplified to be a key anti-fungal agent and exhibited in vitro antifungal activities against Aspergillusfumigatus, C. glabrata, C. tropicalis, A. flavus, C. krusei, and C. parapsilosi. In addition to this, NIH researchers have claimed the efficacy of drugs in animal prototypes of Pneumocystis carinii infection. Apparently, Caspofungin is also used in empirical treatment of patients suffering from febrile neutropenia as well as those with common & serious fungal infections. All these therapeutic features of the medicine is likely to bolster the growth of the Caspofungin market over the forecast timeline.
Furthermore, it has also proved to be effective as rescue treatment in treating patients affected due to invasive aspergillosis and treating of oropharyngeal, disseminated, & esophageal candidiasis. Reportedly, the medicine has proved effective in providing treatment to mucosal & invasive candidiasis. Apparently, the drug has beneficial pharmacokinetic features and cannot be metabolized via cytochrome CYP enzyme. This, in turn, will accentuate the expansion of Caspofungin market over the upcoming years. However, harmful effects related to intake of Caspofungin include chills, phlebitis, rash, headache, diarrhea, fever, abdominal pain, nausea, tachycardia, and vomiting. This will hamper the market growth over the estimated timeline. In addition to this, Caspofungin releases histamine in peripheral cells or blood, thereby resulting in creation of histamine- mediated symptoms in patients that can culminate into serious or fatal anaphylaxis. For the record, the use of the drug is not recommended for pregnant women in the countries like the U.S. This, in turn, can prove detrimental to the growth of the industry over the forecasting timespan.
North American To Establish Leading Position In Market By 2026
The expansion of Caspofungin market in the sub-continent over the forecast timeline can be credited to huge patient population base & presence of key pharmaceutical firms in the countries like the U.S. and Canada. In addition to this, a prominent surge in the aging population in these countries will prop up the growth of Caspofungin business in the North American region over the forecast timespan.
Key players profiled in the report include Merck & Co., Inc., Mylan N.V., Xellia Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, and Gland Pharma Limited.
The global Caspofungin market is segmented as follows:
By Distribution Channel
The drug has proved to be the best therapeutic alternative for treating subjects suffering due to candida infections, aspergillus infections, and candida esophagitis. Apparently, Caspofungin is also used in empirical treatment of patients suffering from febrile neutropenia as well as those with common & serious fungal infections. All these therapeutic features of the medicine is likely to bolster the growth of the Caspofungin market over the forecast timeline.
The CAGR of the industry is expected to be nearly 0.21% during the forecast timeline.
North America will contribute remarkably towards the global market share over the estimated timeline.
The key market players include Mylan N.V., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Merck & Co., Inc., Xellia Pharmaceuticals, and Gland Pharma Limited.